Cardiac fibrosis
Open accessThe DOI matches its Crossref record; 612 of the 615 references it cites were found in a registry or an index.
Abstract
Myocardial fibrosis, the expansion of the cardiac interstitium through deposition of extracellular matrix proteins, is a common pathophysiologic companion of many different myocardial conditions. Fibrosis may reflect activation of reparative or maladaptive processes. Activated fibroblasts and myofibroblasts are the central cellular effectors in cardiac fibrosis, serving as the main source of matrix proteins. Immune cells, vascular cells and cardiomyocytes may also acquire a fibrogenic phenotype under conditions of stress, activating fibroblast populations. Fibrogenic growth factors (such as transforming growth factor-β and platelet-derived growth factors), cytokines [including tumour necrosis factor-α, interleukin (IL)-1, IL-6, IL-10, and IL-4], and neurohumoral pathways trigger fibrogenic signalling cascades through binding to surface receptors, and activation of downstream signalling cascades. In addition, matricellular macromolecules are deposited in the remodelling myocardium and regulate matrix assembly, while modulating signal transduction cascades and protease or growth factor activity. Cardiac fibroblasts can also sense mechanical stress through mechanosensitive receptors, ion channels and integrins, activating intracellular fibrogenic cascades that contribute to fibrosis in response to pressure overload. Although subpopulations of fibroblast-like cells may exert important protective actions in both reparative and interstitial/perivascular fibrosis, ultimately fibrotic changes perturb systolic and diastolic function, and may play an important role in the pathogenesis of arrhythmias. This review article discusses the molecular mechanisms involved in the pathogenesis of cardiac fibrosis in various myocardial diseases, including myocardial infarction, heart failure with reduced or preserved ejection fraction, genetic cardiomyopathies, and diabetic heart disease. Development of fibrosis-targeting therapies for patients with myocardial diseases will require not only understanding of the functional pluralism of cardiac fibroblasts and dissection of the molecular basis for fibrotic remodelling, but also appreciation of the pathophysiologic heterogeneity of fibrosis-associated myocardial disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inflammation and tissue fibrosis co-exist and are causally linked to organ dysfunction1,2.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [2]
In the citing paper
“Among stromal cell types, fibroblasts are of particular interest given their role in tissue fibrosis, arrhythmias, and heart failure 16,29,30 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [30]
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495 · cited 1×
“Fibrosis is an important cause of organ dysfunction in many different diseases, including interstitial lung diseases, liver cirrhosis, progressive systemic sclerosis, and diabetic nephropathy.(1)”
BackgroundMyofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Obesity and the risk of heart failure
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., Kannel, W. B., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020245 · Cited by 3,093
Ignotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis
Prabhu, S. D., & Frangogiannis, N. G. (2016) · Circulation Research · doi:10.1161/circresaha.116.303577 · Cited by 2,224
Self-citationEndothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222 · cited 2×
“The antifibrotic effects were attributed to blockade of TGF-b signalling and were associated with attenuated endothelial to mesenchymal transition.(22,247) Moreover, gain-of-function studies have”
BackgroundHinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Cited by
Items 301–400 of 1,000
Research Progress of Fibroblasts in Human Diseases
Li, X., Li, N., Wang, Y., Han, Q., & Sun, B. (2024) · Biomolecules · doi:10.3390/biom14111478 · Cited by 21
“In addition, PDGF, the Wnt/ β -catenin axis, and other factors also participate in the activation of Fbs [141].”
Salido-Medina, A. B., Gil, A., Expósito, V., Martínez, F., Redondo, J. M., Hurlé, M. A., Nistal, J. F., & García, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112910 · Cited by 21
“[9,10] In particular, TGF-β 1 acts as a powerful promoter of fibrosis by inducing endothelial-to-mesenchymal transition, fibroblast proliferation, and transdifferentiation of these cells into myofibroblasts [10 – 15].”
BackgroundGaydarski, L., Petrova, K., Stanchev, S., Pelinkov, D., Iliev, A. A., Dimitrova, I. N., Kirkov, V., Landzhov, B. V., & Stamenov, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094022 · Cited by 22
Schommer, N., Gendron, N., Krauel, K., Bruggen, S. V., Jarrot, P., Maier, A., Chan, W., Langer, H. F., Duerschmied, D., Westermann, D., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf963 · Cited by 22
Amendola, A., Garoffolo, G., Songia, P., Nardacci, R., Ferrari, S., Bernava, G., Canzano, P., Myasoedova, V. A., Colavita, F., Castilletti, C., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab082 · Cited by 19
Srinivas, B., Bourdi, A., O'Regan, J. D., Malavalli, K. D., Rhaleb, N., Belmadani, S., & Matrougui, K. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029668 · Cited by 19
Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration
Kishore, R., & Magadum, A. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11020038 · Cited by 22
“Under cardiac stress induced by various insults, quiescent cardiac fibroblasts undergo activation, proliferation, and heightened secretion of matrix components [50].”
BackgroundGao, X., Ni, C., Song, Y., Xie, X., Zhang, S., Chen, Y., Wu, H. B. K., Shi, H., Zhang, B., Huang, F., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119070 · Cited by 19
Activation of Imprinted Gene PW1 Promotes Cardiac Fibrosis After Ischemic Injury
Kou, S., Lu, Z., Deng, D., Ye, M., Yu, S., Qin, L., Feng, T., Jiang, Z., Meng, J., Lin, C., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.070738 · Cited by 19
Betz, I. R., Qaiyumi, S. J., Goeritzer, M., Thiele, A., Brix, S., Beyhoff, N., Grune, J., Klopfleisch, R., Greulich, F., Uhlenhaut, N. H., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312695 · Cited by 19
“Nevertheless, stressed cardiomyocytes are able to activate proinflammatory and pro-fibrotic pathways [52].”
BackgroundHaykal, R., Kassar, A., Chamoun, N., & AKOUM, N. W. (2025) · Heart Rhythm O2 · doi:10.1016/j.hroo.2025.04.007 · Cited by 22
Tuleta, I., & Frangogiannis, N. G. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00403.2025 · Cited by 20
Self-citationLuo, S., Ye, D., Zhang, Y., Wang, Y., Zhou, M., Lv, M., Wang, X., Zhong, K., Zhang, Y., Hu, L., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.075903 · Cited by 21
Zeng, K.-F., Wang, H., Deng, B., Chen, T.-F., Chen, J.-B., Ding, W.-J., Chen, S., Xie, J.-D., Lu, S.-M., Chen, G.-H., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155118 · Cited by 18
USP38 regulates inflammatory cardiac remodeling after myocardial infarction
Gong, Y., Kong, B., Shuai, W., Chen, T., Zhang, J., & Huang, H. (2023) · Clinical Science · doi:10.1042/cs20230728 · Cited by 18
Singh, S. K., Gaur, A., Sharma, R. K., Kumari, R., Prakash, S., Kumari, S., Chaudhary, A. D., Prasun, P., Pant, P., Hunkler, H. J., et al. (2023) · Basic Research in Cardiology · doi:10.1007/s00395-023-01016-y · Cited by 19
“Reparative fibrosis due to cardiomyocyte death is a common phenomenon in the heart [8].”
BackgroundLi, L., Ran, Y., Wen, J., Lu, Y., Liu, S., Li, H., & Cheng, M. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010279151240116103917 · Cited by 18
Stromal Cell-SLIT3/Cardiomyocyte-ROBO1 Axis Regulates Pressure Overload-Induced Cardiac Hypertrophy
Liu, X., Li, B., Wang, S., Zhang, E., Schultz, M. L., Touma, M., da Rocha, A. M., Evans, S. Μ., Eichmann, A., Herron, T. J., et al. (2024) · Circulation Research · doi:10.1161/circresaha.122.321292 · Cited by 18
Zhou, R., Xia, Y., Li, Z., Wu, L., Shi, Y. P., Ling, Z., & Zhang, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-55996-5 · Cited by 19
Wang, X., Yang, G., Li, J., Meng, C., & Xue, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-60945-3 · Cited by 19
“Myocardial fibrosis is the process of extracellular ECM deposition between myocardial cells, leading to remodeling and stiffening of the heart tissue 31 .”
BackgroundZhang, A., Wang, J., Hu, Y., Qiu, Y., & Dong, C. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131982 · Cited by 24
m6A control programmed cell death in cardiac fibrosis
Liu, Z., You, Q.-Y., Liu, Z., Lin, L.-C., Yang, J., & Tao, H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122922 · Cited by 18
Molecular mechanisms of regulation of IL-1 and its receptors
Zhukova, J., Lopatnikova, J., Alshevskaya, A., & Sennikov, S. V. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.09.004 · Cited by 20
Qian, H., & Chen, L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112340 · Cited by 19
Molecular insight into arrhythmogenic cardiomyopathy caused by DSG2 mutations
Zhang, B., Wu, Y., Yang, X., Xiang, Y., & Yang, B. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115448 · Cited by 17
Zhong, L., Li, J., Yu, J., Cao, X., Du, J., Liang, L., Yang, M., Yue, Y., Zhao, M., Zhou, T., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117250 · Cited by 19
Molecular mechanism of triptolide in myocardial fibrosis through the Wnt/β-catenin signaling pathway
Zhang, Y., & Lu, F. (2024) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2023.2295785 · Cited by 17
“…is replaced by fibrotic scars produced by fibroblasts and myofibroblasts, resulting in a decrease in the ventricular wall compliance, a reduction in the heart’s diastolic and systolic function, and ultimately leading to serious consequences such as heart failure or even cardiac rupture [4,5].”
Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit
Massoud, G., Parish, M. A., Hazimeh, D., Moukarzel, P., Singh, B., Vaught, K. C. C., Segars, J., & Islam, M. S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112423 · Cited by 17
The role of RNA m6A demethylase ALKBH5 in the mechanisms of fibrosis
Liao, Z., Wang, J., Xu, M., Li, X., & Xu, H. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1447135 · Cited by 17
“Activation of fi broblasts and their transformation into myo fi broblasts were crucial steps in fi brosis (Frangogiannis, 2021).”
BackgroundLi, J., Yushanjiang, F., Fang, Z., & Liu, W. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70141 · Cited by 19
“4 Therefore, how to effectively reduce myocardial interstitial fibrosis is an important strategy to prevent and treat heart failure after MI. Epitranscriptomic RNA modifications play a significant role in regulating gene expression and impacting various cellular and biological functions.”
BackgroundEpigenetic regulation of mitochondrial fission and cardiac fibrosis via sFRP3 promoter methylation
Jiang, S.-X., Zhou, Z., Tu, B., Song, K., Lin, L.-C., Liu, Z., Cao, W., Zhao, J., & Tao, H. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05516-5 · Cited by 17
Wang, Y., Anesi, J., Panicker, I. S., Cook, D., Bista, P., Fang, Y., & Oqueli, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062553 · Cited by 17
“Additionally, treatment with β -adrenergic receptor blockers partially corrected these imbalances in neutrophil and lymphocyte numbers, suggesting that sympathetic activation plays a role in the observed neutrophilia and lymphocytopenia in heart failure patients.”
Moccia, F. D., Totaro, A., Guerra, G., & Testa, G. (2025) · Biomedicines · doi:10.3390/biomedicines13030734 · Cited by 18
Role of Known Transient Receptor Potential Vanilloid Channels in Modulating Cardiac Mechanobiology
Miller, M., Koch, S. E., Veteto, A. B., Domeier, T. L., & Rubinstein, J. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.734113 · Cited by 17
“…excessive cardiac fibroblast proliferation and activation can lead to elevated myocardial stiffness and predispose Frontiers in Physiology | www.frontiersin.org 10 October 2021 | Volume 12 | Article 734113 hearts to diastolic dysfunction (Biernacka and Frangogiannis, 2011; Frangogiannis, 2021).”
BackgroundTargeting on Nrf2/Sesn2 Signaling to Rescue Cardiac Dysfunction during High-Fat Diet-Induced Obesity
Krause‐Hauch, M., Fedorova, J., Zoungrana, L. I., Wang, H., Fatmi, M. K., Li, Z., Iglesias, M., Slotabec, L. A., & Li, J. (2022) · Cells · doi:10.3390/cells11162614 · Cited by 17
“Many obese patients have been shown to develop fibrosis of the myocardium [27,29].”
BackgroundAdriamycin induces cardiac fibrosis in mice via PRMT5-mediated cardiac fibroblast activation
Dong, X., Yuan, B.-H., Yu, S.-Z., Liu, H., Pan, X., Sun, J. T., & Pan, L. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00963-x · Cited by 16
“Conversion of fibroblasts into secretory, matrix-producing and contractile cells, called myofibroblasts, is a crucial cellular event in cardiac fibrosis [8].”
BackgroundLithium Treatment Improves Cardiac Dysfunction in Rats Deprived of Rapid Eye Movement Sleep
Chen, P., Chung, C., Liu, S.-H., Kao, Y., & Chen, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911226 · Cited by 18
Activating Protein-1 (AP-1): A Promising Target for the Treatment of Fibrotic Diseases
Pi, Z., Qiu, X., Liu, J., Shi, Y., Zeng, Z., & Xiao, R. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230209100059 · Cited by 17
Isolation and Culture of Primary Fibroblasts from Neonatal Murine Hearts to Study Cardiac Fibrosis
Kumar, S. A., Nagesh, D., Ramasubbu, V., Prabhashankar, A. B., & Sundaresan, N. R. (2023) · BIO-PROTOCOL · doi:10.21769/bioprotoc.4616 · Cited by 17
Werner, F., Santos, E. P., Michel, K., Schrader, H., Völker, K., Potapenko, T., Krebes, L., Abeßer, M., Möllmann, D., Schlattjan, M., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.160416 · Cited by 16
The role of mammalian Sirtuin 6 in cardiovascular diseases and diabetes mellitus
Wu, K., Wang, Y., Liu, R., Wang, H., & Tao, R. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1207133 · Cited by 16
“Frontiers in Physiology frontiersin.org10 fibroblasts and increase of myofibroblasts, accelerates the pathological process of cardiac remodeling (Frangogiannis, 2021).”
BackgroundClaridge, B., Rai, A., Lees, J. G., Fang, H., Lim, S. Y., & Greening, D. W. (2023) · Journal of Extracellular Biology · doi:10.1002/jex2.125 · Cited by 18
Alonazi, A. S., Dayel, A. F. B., Albuaijan, D. A., Osfur, A. S. B., Hakami, F. M., Alzayed, S. S., Almotairi, A. R., Khan, M. R., Alharbi, H. M., Ali, R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417270 · Cited by 17
Mimouni, M., Lajoix, A., & Desmetz, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010382 · Cited by 17
“Finally, angiotensin II (Ang II), a major fibrosis inducer [3], is also able to induce EndMT by activating NF κ B signaling and pro-inflammatory cytokine production in HUVEC [45–48] in HMVEC [49] and in HCAEC [50].”
BackgroundInfluentialDeleterious Anti-Inflammatory Macrophage Recruitment in Early Post-Infarction Phase
Paccalet, A., Badawi, S., Pillot, B., Augeul, L., Mechtouff, L., Harhous, Z., Gouriou, Y., Paillard, M., Breuilly, M., Amaz, C., et al. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.01.019 · Cited by 16
Muthalaly, R. G., Tan, S., Nelson, A. J., Abrahams, T., Han, D., Tamarappoo, B. K., Dey, D., Nicholls, S. J., Lin, A., & Nerlekar, N. (2024) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2024.06.002 · Cited by 16
Islam, K. N., Nguyen, I. D., Islam, R. K., Pirzadah, H., & Malik, H. (2024) · Cureus · doi:10.7759/cureus.64913 · Cited by 19
“As a result, the fibrosis prevents cardiac rupture, but diastolic or systolic function will be impaired [51].”
BackgroundZhang, B., Wu, Y., Zhou, C., Xie, J., Zhang, Y., Yang, X., Xiao, J., Wang, D. W., Shan, C., Zhou, X., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03593-8 · Cited by 17
“As the master regulator of fibrosis, TGF-β1 plays a pivotal role in cardiac fibrosis and is upregulated under stress, inflammation, fibrosis, and myocardial injury [33].”
BackgroundSuzuki, Y., Emoto, T., Sato, S., Yoshida, T., Shoda, M., Endoh, H., Nagao, M., Hamana, T., Inoue, T., Hayashi, T., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-07308-w · Cited by 17
Mamazhakypov, A., Sommer, N., Aßmus, B., Tello, K., SCHERMULY, R. T., Kosanovic, D., Шогаибович, С. А., Weißmann, N., & Pak, O. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18168297 · Cited by 16
“In various LV pathologies, the extent and severity of myocardial fibrosis are associated with adverse outcome [37].”
BackgroundGharraee, N., Wang, Z., Pflum, A., Medina-Hernández, D., Herrington, D. M., Zhu, X., & Meléndez, G. C. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100292 · Cited by 16
Liu, P., Dong, X., Dong, C., Hou, G., Liu, W., Jiang, X. M., & Xin, Y. (2023) · Antioxidants · doi:10.3390/antiox12030672 · Cited by 19
“The other 70% of cells comprise endothelial cells, fibroblasts, smooth muscle cells and immune cells [40,41].”
BackgroundLi, Y., & Guo, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1189007 · Cited by 17
“Excessive lactic acid induces the proliferation and differentiation of myofibroblasts through pH- and TGF-b1 pathway, which leads to the aggravation of myocardial fibrosis (99, 100).”
BackgroundHeart-on-a-chip and vasculature-on-a-chip platforms as models of cardiovascular disease
Khosravi, R., & Radisic, M. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01255-1 · Cited by 18
TRIM44 aggravates cardiac fibrosis after myocardial infarction via TAK1 stabilization
Qian, H., Lu, Z., Hao, C., Zhao, Y., Bo, X., Hu, Y., Zhang, Y., Yao, Y., Ma, G., & Chen, L. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110744 · Cited by 15
MicroRNAs and cardiac fibrosis: A comprehensive update on mechanisms and consequences
Gocer, Z., Elek, A., Caska, H., & Bozgeyik, İ. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154853 · Cited by 15
Elsayed, M. O. K., Moustafa, Y. M., Mehanna, E. T., Elrayess, R. A., El-Sayed, N. M., & Hazem, R. M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122354 · Cited by 16
Nur77 alleviates cardiac fibrosis by upregulating GSK-3β transcription during aging
Zhang, T., Ma, R., Li, Z., Liu, T., Yang, S., Li, N., & Wang, D. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176290 · Cited by 16
Mast Cells in Cardiac Remodeling: Focus on the Right Ventricle
Mamazhakypov, A., Maripov, A., Шогаибович, С. А., SCHERMULY, R. T., & Sydykov, A. S. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11020054 · Cited by 15
E3 ubiquitin ligase WWP2 as a promising therapeutic target for diverse human diseases
You, S., Xu, J., Guo, Y., Guo, X., Zhang, Y., Zhang, N., Sun, G., & Sun, Y. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101257 · Cited by 15
Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells
Zhang, Q., Dai, J., Liu, T., Rao, W., Li, D., Gu, Z., Huang, L., Wang, J., & Hou, X. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05134-6 · Cited by 15
“For example, In cases of extensive myocardial infarction, the loss of contractile cells due to pressure and volume overload can lead to progressive interstitial fibrosis in the border zone and distal myocardium [11].”
Ca2+ Signaling in Cardiovascular Fibroblasts
Rinne, A., & Pluteanu, F. (2024) · Biomolecules · doi:10.3390/biom14111365 · Cited by 15
Protective effect of UDCA against IL-11- induced cardiac fibrosis is mediated by TGR5 signalling
Reilly-O’Donnell, B., Ferraro, E., Tikhomirov, R., Núñez-Toldrà, R., Shchendrygina, A., Patel, L., Wu, Y., Mitchell, A., Endo, A., Adorini, L., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1430772 · Cited by 19
Pivotal Role of miRNA–lncRNA Interactions in Human Diseases
Pooresmaeil, F., Azadi, S., Hasannejad-Asl, B., Takamoli, S., & Bolhassani, A. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01343-y · Cited by 16
“As reported by the World Health Organization, CVDs represent the primary cause of mortality on a global scale [94, 95].”
Retinoic acid signaling and metabolism in heart failure
Parker, L. E., Papanicolaou, K. N., Zalesak‐Kravec, S., Weinberger, E. M., Kane, M. A., & Foster, D. B. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00871.2024 · Cited by 17
Circular PVT1 promotes cardiac fibroblast activation interacting with miR-30a-5p and miR-125b-5p
Bibi, A., Madè, A., Greco, S., García-Manteiga, J. M., Tascini, A. S., Tastsoglou, S., Zaccagnini, G., Leszek, P., Gaetano, C., & Martelli, F. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07652-7 · Cited by 16
Emerging Epigenetic Therapies for the Treatment of Cardiac Fibrosis
Garitano, N., Aguado‐Alvaro, L. P., & Pelacho, B. (2025) · Biomedicines · doi:10.3390/biomedicines13051170 · Cited by 16
“Reactive fibrosis occurs in response to chronic stressors such as hypertension, obesity, diabetes, or aging [8].”
TGF-β-Driven Atrial Fibrosis in Atrial Fibrillation: From Mechanistic Insights to Targeted Therapies
Chen, C., Chen, P., Yu, W., Zhao, L., Yu, Y., Qu, H., Fu, C., Shi, D., & Guo, M. (2025) · Aging and Disease · doi:10.14336/ad.2025.0564 · Cited by 21
Iop, L., Iliceto, S., Civieri, G., & Tona, F. (2021) · Cells · doi:10.3390/cells10113175 · Cited by 16
Shi, L., Du, X., Zuo, B., Hu, J., & Cao, W.-F. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/2894659 · Cited by 15
“,ese substances, as proinflammatory mediators, stimulate the proliferation and activation of the resident fibroblasts and their transformation into myofibroblasts [36], thus promoting the deposition of matrix proteins in the ECM.”
BackgroundInfluentialCirculated TGF-β1 and VEGF-A as Biomarkers for Fabry Disease-Associated Cardiomyopathy
Ivanova, M. M., Dao, J., Slayeh, O. A., Friedman, A., & Göker-Alpan, Ö. (2023) · Cells · doi:10.3390/cells12162102 · Cited by 15
“The active-TGF-β is a pro-migratory factor that recruits myofibroblasts for tissue repair/remodeling in response to inflammation or injury [31,54].”
BackgroundTargeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure
Amrute, J. M., Luo, X., Penna, V., Bredemeyer, A., Yamawaki, T., Heo, G. S., Shi, S., Koenig, A., Yang, S., Kadyrov, F., et al. (2022) · bioRxiv · doi:10.1101/2022.10.17.512579 · Cited by 14
Yan, X., Wang, R., Xu, H., Tao, Z., & Ling, J. (2025) · Medical Principles and Practice · doi:10.1159/000548233 · Cited by 14
Strizzi, C. T., D’Ambrosio, V., Grandaliano, G., & Pesce, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188829 · Cited by 15
“In the heart, for instance, MR activation in cardiomyocytes and cardiac fibroblasts promotes myocardial fibrosis, leading to diastolic dysfunction and contributing to the pathophysiology of HFpEF [36–38].”
Role of cGAS-STING pathway in fibrotic disease
Feng, L., Zhang, F., Cao, J., & Xiong, W. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107971 · Cited by 15
Bengel, F. M., Hess, A., Diekmann, J., & Thackeray, J. T. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01242-y · Cited by 16
Lee, E., Liu, Z., Nguyen, N., Nairn, A. C., & Chang, A. N. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102296 · Cited by 14
“Cardiac remodeling processes that include marked fibrosis and contractile dysfunction point to among others, activation of inflammatory pathways (27).”
BackgroundXiao, Z., Wei, X., Li, M., Yang, K., Chen, R., Su, Y., Yu, Z., Liang, Y., & Ge, J. (2023) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2023.08.006 · Cited by 14
RuizdelRio, J., Guedes, G., Novillo, D., Lecue, E., Palanca, A., Cortajarena, A. L., & Villar, A. V. (2023) · Theranostics · doi:10.7150/thno.85409 · Cited by 15
Ou, J., Tao, H., Bao, Q., Dai, Y., Wang, Q., Chen, Q., Feng, Y., & Meng, X. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c05603 · Cited by 14
Angeli, E., Jordan, M., Otto, M., Stojanović, S. D., Karsdal, M. A., Bauersachs, J. K., Thum, T., Fiedler, J., & Genovese, F. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.02.008 · Cited by 15
Badmus, O. O., da Silva, A. A., Li, X., Taylor, L. C., Greer, J. R., Wasson, A. R., McGowan, K., Patel, P. R., & Stec, D. E. (2024) · FASEB BioAdvances · doi:10.1096/fba.2023-00139 · Cited by 14
“33 There is mounting evidence that accumulation of extracellular matrix within the myocardium is a good biomarker of myocardial fibrosis.”
BackgroundComprehensive macro and micro views on immune cells in ischemic heart disease
Zhao, Y., Tan, M., Yin, Y., Zhang, J., Song, Y., Li, H., Lin, Y., Jin, Y., Wu, Z., Yang, T., et al. (2024) · Cell Proliferation · doi:10.1111/cpr.13725 · Cited by 15
“88,89 This evidence underscores that the involvement of macrophages in the reparative process post-IHD is not indiscriminate but rather operates within a dynamic equilibrium.”
Wang, J., Li, J., Su, G., Zhang, Y., Wang, Z., Jia, Y., Yu, Q., Shen, Z., Zhang, Y., & Yu, Y. (2024) · Regenerative Biomaterials · doi:10.1093/rb/rbae145 · Cited by 16
Protein prenylation in mechanotransduction: implications for disease and therapy
Chen, H., Yang, J., Yang, Q., Jia, Y., & Guo, X. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.008 · Cited by 14
Functions of the Muscleblind-like protein family and their role in disease
Zhou, H., Xu, J., & Pan, L. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02102-5 · Cited by 14
“However, overactivation of this fibrotic response leads to cardiac dysfunction and heart failure [113, 114].”
Direct fibroblast reprogramming: an emerging strategy for treating organic fibrosis
Lin, H., Wang, X., Chung, M., Cai, S., & Pan, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06060-3 · Cited by 14
“Cardiac myofibroblasts are enriched around the injured area in the early period and release massive ECM [16].”
Chen, S., Zeng, X., Wu, M., Zhu, J., & Wu, Y. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.036887 · Cited by 16
“9–11 In recent years, regenerative medicine and tissue engineering have brought new hope for the treatment of MI. Sodium alginate (SA) has become a commonly used drug delivery system due to its advantages in long-term storage, transportation, and use.”
Jin, M., Li, C., Wu, Z., Tang, Z., Xie, J., Wei, G., Yang, Z., Huang, S., Chen, Y., Li, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202414830 · Cited by 17
Amphiregulin in Fibrotic Diseases and Cancer
Kim, T. R., Son, B., Lee, C. G., & Park, H.-O. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146945 · Cited by 14
“A large number of studies suggested that the extent of cardiac fibrosis was associated with poor prognoses, but it may indicate the activation of normal wound healing [140].”
Sharma, A., Blasio, M. J. D., & Ritchie, R. H. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15820 · Cited by 14
The emerging role of leptin in obesity-associated cardiac fibrosis: evidence and mechanism
Mao, Y., Zhao, K., Li, P., & Sheng, Y. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04562-6 · Cited by 15
Sasi, A., Romaine, A., Erusappan, P. M., Melleby, A. O., Hasic, A., Dahl, C. P., Broch, K., Almaas, V. M., Puertas, R. D., Roderick, H. L., et al. (2023) · Matrix Biology Plus · doi:10.1016/j.mbplus.2023.100135 · Cited by 14
“Cardiac fibrosis is a central pathological feature in several cardiac diseases, including heart failure [1].”
BackgroundThe inhibition of FTO attenuates the antifibrotic effect of leonurine in rat cardiac fibroblasts
Meng, Y., Xi, T., Fan, J., Yang, Q., Yang, J., & Yang, J. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149375 · Cited by 14
Zhao, K., Mao, Y., Ye, X., Ma, J., Sun, L., Li, P., & Li, Y. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174587 · Cited by 14
Targeting macrophage–fibroblast interactions in the failing heart
Frangogiannis, N. G. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01112-z · Cited by 15
Self-citationYouness, M., Ekhteraei‐Tousi, S., Nagaraju, C. K., Puertas, R. D., Thienpont, B., Rega, F., Sipido, K. R., & Roderick, H. L. (2025) · Genome Medicine · doi:10.1186/s13073-025-01580-z · Cited by 17
“Genes upregulated in FB4 vs FB1 including COL22A1 , CTHRC1, COL1A1 , CILP , and COMP that contribute to TGF-β signalling, ECM deposition and MyoFB activation are consistent with FB4 being of a more activated state than FB1 [9, 24, 32, 64–67].”
InfluentialLin, X.-Y., Chu, Y., Zhang, G., Zhang, H.-L., Kang, K., Wu, M., Zhu, J., Xu, C., Lin, J., Huang, C.-K., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121936 · Cited by 13
Wang, A., Ma, H., Yi, Y.-L., Zhu, S., Yu, Z.-W., Zhu, J., Mei, S., Bahetibike, S., Lu, Y.-Q., Huang, L., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176116 · Cited by 16
Hyperoside Protects Trastuzumab-Induced Cardiotoxicity via Activating the PI3K/Akt Signaling Pathway
Wei, S., Ma, W., Xie, S., Liu, S., Xie, N., Li, W., Zhang, B., & Liu, J. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07522-4 · Cited by 13
“Myocardial fibrosis involves various injuries leading to inflammatory responses and the mass production of extra-cellular matrix, thus interrupting electrophysiological functions, which reduces myocardial compliance and causes heart failure [19].”
Metadata
- Authors
- Frangogiannis, N. G.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Frangogiannis, Nikolaos G
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-02
- Volume
- 117
- Issue
- 6
- Pages
- 1450-1488
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- PMC
- PMC8152700
- OpenAlex
- W4210607007
- Cited by
- 1,229
- References
- 615
- Citations by year
- 2026: 265 · 2025: 319 · 2024: 273 · 2023: 210 · 2022: 130 · 2021: 32
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Cardiovascular Research (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH (R01 HL76246, R01 HL85440, R01 HL149407)
- U.S. Department of Defense (PR151134, PR151029, PR181464)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- myocardial fibrosis, myocardial fibroblasts, myofibroblasts, extracellular matrix deposition, TGF-beta, platelet-derived growth factor, cytokines, mechanoreceptors, integrins, pressure overload, myocardial infarction, heart failure, familial cardiomyopathy, diabetic cardiomyopathy, cardiac arrhythmias
- MeSH terms
- Antifibrotic Agents, Animals, Extracellular Matrix, Fibroblasts, Fibrosis, Humans, Cardiomyopathies, Myocytes, Cardiac, Mechanotransduction, Cellular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.